ZENTALIS PHARMACEUTICA

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Aug 2022 17:10:35 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary

27 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in the Jefferies Healthcare Conference

01 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

31 May 2022 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock

18 May 2022 16:01:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock

16 May 2022 07:28:36 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer

16 May 2022 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update

05 May 2022 07:00:03 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer

27 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR

11 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR

08 Apr 2022 13:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3

29 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis

22 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference

09 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022

08 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

24 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

03 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021

02 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma

17 Nov 2021 07:00:00 By Nasdaq GlobeNewswire